Povorcitinib
Small moleculeexperimental
Clinical trial activity
23 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
16
Phase 3
8
Phase 4
0
Earliest trial started Jun 11, 2018 (NCT03569371)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase JAK1INHIBITOR
JAK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1n[nH]c(C)c1-c1cnn(C2(CC#N)CN(c3cc(F)c(C(=O)N[C@@H](C)C(F)(F)F)cc3F)C2)c1- Mol. weight
- 507.47 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095079 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07213973 | Phase 2 | Dec 14, 2025 | Incyte |
| NCT06855498 | Phase 3 | Feb 28, 2025 | Incyte |
| NCT06516965 | Phase 3 | Oct 10, 2024 | Incyte |
| NCT06516952 | Phase 3 | Oct 10, 2024 | Incyte |
| NCT06505265 | Phase 1 | Aug 12, 2024 | Incyte |
| NCT06441318 | Phase 1 | Jul 12, 2024 | Incyte |
| NCT06416800 | Phase 1 | Jun 19, 2024 | Incyte |
| NCT06380205 | Phase 1 | May 7, 2024 | Incyte |
| NCT06212999 | Phase 3 | Jan 30, 2024 | Incyte |
| NCT06113445 | Phase 3 | Nov 29, 2023 | Incyte |
| NCT06113471 | Phase 3 | Nov 27, 2023 | Incyte |
| NCT05936567 | Phase 2 | Jul 31, 2023 | Incyte |
| NCT05851443 | Phase 2 | Jul 11, 2023 | Incyte |
| NCT05624710 | Phase 1 | Feb 26, 2023 | Incyte |
| NCT05620836 | Phase 3 | Dec 14, 2022 | Incyte |
| NCT05620823 | Phase 3 | Dec 14, 2022 | Incyte |
| NCT05624723 | Phase 1 | Nov 17, 2022 | Incyte |
| NCT05061693 | Phase 2 | Nov 17, 2021 | Incyte |
| NCT05068466 | Phase 1 | Oct 21, 2021 | Incyte |
| NCT04818346 | Phase 2 | May 6, 2021 | Incyte |
Showing 20 of 23 trials
Page 1 / 2
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Incyte | For profit | 23 | 23 | 3 | 2018 |
1 organizations
Page 1 / 1